Urothelial Carcinoma and Bladder Cancer
Clinical research in urothelial carcinoma spans tumours of the bladder and upper urinary tract, with attention to disease that requires surgery and to rare histological subtypes. The studies also examine neoadjuvant immunotherapy and immune checkpoint inhibition in relation to tumour shrinkage and immune activity.
- Neoadjuvant immune checkpoint inhibitors
- Pathological complete response
- Upper urinary tract malignancy
- Rare histological subtypes
Research activity in this area also includes maintenance avelumab and treatment strategies for advanced urothelial cancer.
Triple-Negative Breast Cancer
Work in triple-negative breast cancer focuses on both PD-L1-negative metastatic disease and broader neoadjuvant treatment approaches in women with this aggressive breast cancer subtype. The trials examine combinations involving antibody-drug conjugates, immune checkpoint blockade, and chemotherapy.
- PD-L1-negative metastatic triple-negative breast cancer
- Datopotamab deruxtecan combinations
- Neoadjuvant therapy
- Progression-free survival
The breast cancer portfolio reflects interest in treatment resistance, tumour biology, and response in advanced metastatic disease.
Rheumatoid Arthritis
Research in rheumatoid arthritis centres on precision therapy and synovial tissue biomarkers to guide selection of biologic treatment. The studies explore molecular signatures linked to response in patients starting therapies such as anti-TNF agents, IL-6 inhibitors, and abatacept.
- Synovial molecular profiles
- CD80/CD86 biomarkers
- Biologic therapy response
- Early rheumatoid arthritis
These studies also include evaluation of drug target signatures from synovial tissue to support treatment matching in inflammatory arthritis.
Precision Oncology and Immune Signalling
Across its cancer studies, the sponsor shows interest in immune-oncology and molecularly informed treatment selection, including assessment of PIK3CA, AKT1, and PTEN alterations in relation to treatment response. The research also examines how immune and tumour-targeted approaches interact in solid tumours.
- PIK3CA/AKT1/PTEN genetic alterations
- Immune response
- Targeted therapy combinations
- Solid tumour biology
This area links biomarker-driven oncology with treatment strategies for urothelial and breast cancers.
